Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same

US6217866A · kind A · utility

Assignee

• Rhone-Poulenc Rorer International (Holdings), Inc. · US

Inventors

• Joseph Schlessinger · New York, US
• David Givol · Rehovot, IL
• Francoise Bellot · Fresnes, FR
• Richard Kris · Tucson, US
• George A. Ricca · Blue Bell, US
• Christopher Scott Atherton Cheadle · West Chester, US
• Victoria J. South · Collegeville, US

Key dates

• Filing date: Jun 7, 1995
• Grant date: Apr 17, 2001
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.